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Abstract
Objectives: Hepacare is a widely marketed herbal
formulation in Nigeria for treating chronic liver ailments.
This study evaluated the safety, as well as pro-
inflammatory and genotoxicity effects, of Hepacare in
mice.
Methods: The effect of the formulation was estimated in
a 28-day study where 25 mice were divided into five
groups, and Hepacare was orally administered at 250,
500, 750 and 2500 mg/kg body weight. The biochemical
and haematological parameters were determined, organ
weights were estimated and histopathology was also
conducted. mRNA expression of the pro-inflammatory
cytokines, TNF-a and IL-6 was estimated by RT-PCR
in acute toxicity experiments.
Results: The LD50 was calculated at 3807.89 mg/kg body
weight in mice. There was a significant increase (p < 0.05)
in the ALP activity in the 750 mg/kg treated group, while
the 2500 mg/kg group exhibited significant increases in
their AST, ALT, ALP, total bilirubin and total protein
levels compared with the control group. However, there
was a significant dose related increase in monocytesy. This is an open access article under the CC BY-NC-ND license
.1016/j.jtumed.2017.02.004
A.H. Adebayo et al.314counts in the groups treated with 750 and 2500 mg/kg.
There was no significant difference (p > 0.05) in TNF-a
and IL-6 mRNA expression in the genotoxicity studies in
all of the treatment groups compared with the control.
However, several hepatic and nephro-pathological de-
rangements were observed in the groups treated with
higher doses of the formulation.
Conclusions: The study established that the herbal
formulation may not induce significant pro-inflammatory
toxic responses and genotoxic effects, but prolonged
intake of higher doses may cause severe biochemical and
clinical abnormalities.
Keywords:Genotoxicity; Hepacare; Herbal formulation; Pro-
inflammation; Toxicity studies
 2017 The Authors.
Production and hosting by Elsevier Ltd on behalf of Taibah
University. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).Introduction
Plants, extracts and their formulations have been used for
centuries in therapy for various ailments and conditions.
Plants contain phytochemical and secondary metabolites,
which form the active compounds responsible for their
therapeutic property. Despite these plants and extracts’
derived benefits, inappropriate use of medicinal plants or
drugs from herbal origins may lead to an overdose of these
plant products, which contain these phytochemicals, a
number of which may cause toxic reactions to animals or
even human beings.1,2 However, most herbal medicines lack
proper documentation for their potential toxicity and they
rarely require a professional to prescribe their use.3 The
reason why plant drugs are seemingly without restriction
for use and do not undergo the rigours of testing that
other drug classes undergo is because plants fall under the
food class4 and they are mostly marketed as supplements.5
Fortunately, plants, especially those without immediate,
observable harm after consumption, rarely ever have side
effects.3,6
There are numerous traditional plant formulations
available for the treatment of various diseases. A botanical
market review revealed that remedies from natural origins
account for a $1.8 billion market in the United States. For
example, a single herbal preparation, Silymarin, used almost
exclusively for liver diseases, accounted for $180 million in
Germany alone.7 Approximately 600 commercial herbal
formulations with claimed hepatoprotective activities are
being sold all over the world. From these mixtures, more
than 170 phytoconstituents isolated from 110 plants
belonging to 55 families have been reported and
ascertained to possess hepatoprotective activity. Some of
these herbal preparations exist as standardized extracts
with major known ingredients or even pure compounds
that are being evaluated.7 However, only a small
proportion of hepatoprotective plants as well as otherformulation classes used in traditional medicine are
pharmacologically evaluated for their safety and efficacy.8
Hepacare is a formulation prepared using a blend of
indigenous African herbal ingredients. These include Olax
subscorpioidea and Capsicum frutescens. Although used as
a supplement, it is also used as an alternative medical
approach to treat some liver disorders, such as hepatitis
and jaundice. Although there is recent scientific evidence to
support the hepatoprotective properties of this herbal
formulation, a proper toxicological assessment for the drug
has not been performed to date.9
Recently, the Organization for Economic Cooperation
and Development (OECD) guidelines for the testing of
chemicals called for molecular toxicological assessments to
be made on substances of exposure in addition to other
mainstream toxicological procedures.10 This motivated us to
expand our research to include inflammation and
genotoxicity studies that could complement other
indicators of toxicity studies such as, biochemical,
haematological and histopathological assessments. Proper
toxicological evaluation of safety of herbal formulation use
is necessary to establish the benefits of the use of herbal
formulations, which forms the primary motivation of this
study.
Materials and Methods
Chemicals
Drugs and chemicals, including distilled water (DW),
formalin, diethyl ether, agarose, low melting point (LMP)
agarose, boric acid, sodium chloride (NaCl), ethyl-
enediaminetetraacetic acid (EDTA), trizma base, Triton-x,
sodium hydroxide (NaOH), hydrochloric acid (HCl) and
ethidium bromide were purchased from Sigma Aldrich, St.
Louis MO, USA. Cyclophosphamide (Cytoxan) was pur-
chased from a Health Plus Pharmacy in Lagos, Nigeria.
Hepacare sample preparation
Hepacare herbal formulation capsules were purchased
from a pharmaceutical shop in Lagos, Nigeria. The content
of the capsule was ground, dissolved in DW and adjusted to
5 ml/kg body weight for mice to minimize administration
trauma in experimental animals.
Source of animals and housing
Fifty (50) healthy male adult mice weighing between 18
and 22 g were purchased from the University of Agriculture,
Abeokuta, Ogun State, Nigeria. The mice were spaced and
securely caged and maintained to acclimatize at room tem-
perature between 22 and 24 C with a 12 h light/dark cycle in
a well-ventilated, pathogen-free animal facility for seven
days before the commencement of the experiment. Mice
were given feed and water ad libitum during the acclimati-
zation period and for the duration of the experiment daily.
After the experiment, the animals were euthanized. Ethical
approval for the use of animals was obtained from the
Department of Biological Sciences Research Ethics Com-
mittee of Covenant University. All procedure and handling
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for Health (NIH) Guide for the Care and Use of Laboratory
Animals (1984).Acute toxicity evaluation of herbal formulation
The method as described by Lorke11 was used in the
determination of the median lethal dose (LD50) of the
herbal formulation in mice with several modifications. A
total of 18 mice were used for this experiment. The
experiment for the determination of the LD50 of the herbal
formulation was divided into two phases. In the first phase,
the mice were weighed and randomly divided into four
groups. Each group contains three mice. Three groups
received herbal drug (by gavage) at doses of 10, 100 and
1000 mg/kg. The control group was treated only with
distilled water, which was also orally administered. In the
second phase of the experiment, three groups of three mice
per group were weighed and administered with doses of
1600, 2900 and 5000 mg/kg, respectively. In both phases,
the mice were observed for 72 h for delayed mortality, any
abnormal behaviour and other toxic signs. The LD50 was
calculated using a method reported by Lorke11 as the
geometric mean between the minimal lethal dose and the
maximal sub-lethal dose. At the end of the experiment, the
surviving animals were euthanized according to ethical
prescriptions.Acute pro-inflammatory evaluation
The mRNA from liver tissue obtained from mice was
used for experiments, as described in the RNeasy Mini Kit
protocol (Qiagen Inc., Valencia, CA). The kit technology
combined the selective binding properties of a silica-gel-
based membrane with microspin technology and consists
of a high-salt buffer system that permits RNA of up to 200
bases to bind to a silica-gel membrane. The total RNA
binds to the membrane and contaminants are effectively
separated. The procedure favours enrichment for mRNA,
as most RNAs less than 200 nucleotides (such as smaller
rRNA, and tRNAs) are selectively excluded. Liver samples
from each group (control, 250, 500, and 2500 mg/kg) were
lysed and homogenized in the presence of a highly dena-
turing guanidine thiocyanate-containing buffer, which was
used to inactivate RNases to ensure purification of intact
RNA. Ethanol was added to provide appropriate binding
conditions. The RNA concentration contained in 2 ml was
determined using a NanoDrop ND-1000 Spectrophotom-
eter (Thermo Scientific, Wilmington, DE) and the volume
of each sample was normalized to 1 mg of RNA per PCR
combination. Primers of Mouse tumour necrosis factor a
(TNF-a, ID No., X02611), Mouse interleukin 6 (IL-6, ID
No., NM_031168) and Mouse GAPDH (ID No., M32599)
were purchased from Qiagen (Valencia, CA). Real-time
reverse transcriptase polymerase chain reaction (RT-
PCR) was carried out using the Transgen Reverse Tran-
scriptase one-step PCR kit (Transgen Biotech Co, Beijing
China) according to the manufacturer’s manual, using a
Bio-rad C1000 Touch Thermal Cycler (Bio-rad Labora-
tories, Hercules, CA, USA). GAPDH, TNF-a and IL-6
mRNA expression levels and quantification wereperformed with the ImageJ (version 1.48) software (Na-
tional Institutes of Health, WI, USA) as described in
Schneider et al.12
Sub-chronic evaluation of the herbal formulation
Twenty-five male mice were randomly distributed into
five groups with five animals each. The herbal formulation
was orally administered daily for 28 days in single doses of
250, 500, 750, and 2500 mg/kg. The control mice received
only vehicle (DW) and were fed with food and water. Signs of
toxicity and mortality were also recorded daily throughout
the study period. At the end of the experiment, all mice were
anesthetized in diethyl ether, and blood samples were
collected via cardiac puncture into non-heparinized and
EDTA-containing tubes for biochemical and haematological
analysis, respectively. The liver and kidneys were excised and
stored in 10% formalin for histopathology examination.13
Blood sample analysis
Serum was prepared by separating it from whole blood
and centrifuged at 2500 rpm for 10 min. Biochemical indices,
such as aspartate aminotransferase (AST), alanine amino-
transferase (ALT), alkaline phosphatase (ALP), total protein
and bilirubin, were determined using an automated Tc Ma-
trix Tc-3100 Analyser (Teco Diagnostics, CA, United
States). Haematological indices, including packed cell vol-
ume (PCV), total white blood cell (WBC), neutrophil,
lymphocyte and monocyte counts were also quantified using
a Sysmex 8000i Automated Hematology Analyzer (Sysmex
Corporation, Kobe, HYG, Japan).
Histopathological examinations
Histological examinations were performed at the Uni-
versity College Hospital, Ibadan, Nigeria by a licensed
pathologist who was not informed of details of the treatment
groups to eliminate bias. Kidney and liver tissues were
embedded in paraffin, and cut into 5 mm thick sections using
a rotary microtome (RM2125, Leica Microsystems Inc.,
Bannockburn, IL, USA). The sections were stained with
haematoxylin-eosin dye and evaluated under a light micro-
scope with 40 and 400 resolution. Photomicrographs of
the tissue sections were taken and reported.13
Genotoxicity studies
Twelve male mice weighing between 20 and 25 g were used
for the single-cell electrophoresis (comet) assay. The mice
were divided into four groups containing three animals each.
Two of the groups received a single dose of 100 and 1000 mg/
kg b.w. of the formulation dissolved in DW. The control
group received only DW. The fourth group was administered
with reconstituted cyclophosphamide at 100 mg/kg body
weight. The animals were anaesthetized in diethyl ether after
24 h of administration of the treatments. The femur was
obtained for bone marrow and processed to obtained cell
suspensions. The “alkaline” comet assay was performed as
described by Tice et al.14 Slides were pre-coated on one side
in 1% normal agarose (pre-heated to 100 C) by dipping the
A.H. Adebayo et al.316slide in agarose and wiping one slide clean. The slides were
left to dry for 24 h. Cells were suspended in 1% low melting
point agarose (maintained alternatively in water baths of 30
and 70 C) and were subsequently used to coat the previously
coated slides with a micro pipette. After the agarose had
solidified, the slides were placed in cell lysis buffer (100 mM
EDTA; 2.5 M NaCl; 1% Triton-X100, 10 mM Trizma base;
pH¼ 10) for 1 h, after which the slides were transferred to an
alkaline buffer (1 mM EDTA; 300 mMNaOH; pH > 13) for
the DNA unwinding process. The slides were then subjected
to electrophoresis at 25 V and 300 mA for 20 min. The
comets were visualized and captured with the 40 objective
of an EVOS FL Cell Imaging System. The extent of DNA
damage was calculated by image analysis with the Open-
Comet plugin using the software ImageJ (version 1.48)
software.
Statistical analysis
All results are reported as the means and standard error of
the mean (mean  SEM). Statistical evaluations of the data
were initially tested by the homogeneity of variances. Com-
parisons between groups were performed using one way
analysis of variance (ANOVA) followed by Tukey’s multiple
comparison tests using the R statistical programming lan-
guage (version 3.1.1). All comparisons were made relative to
untreated controls (positive control in the case of the geno-
toxic assessment), and differences with a p value <0.05 were
considered to be significant. Data were visualized in figures
with Graph pad prism version 6.
Results
LD50 value
The median lethal dose (LD50) result for Hepacare is
shown in Table 1. The LD50 value was estimated to be
3807.89 mg/kg b.w.
Acute pro-inflammation results
The acute effect of the herbal formulation on IL-6 and
TNF-amRNA expression levels is as shown in Figures 1 and
2. Expression of the quantification by pixel intensity
measurements of the visualized lanes of stained mRNA
after electrophoresis (Figure 1) showed that there was no
significant (p > 0.05) difference between the mRNA
expression of either TNF-a or IL-6 in the groups treated
with 250 and 500 mg/kg dose of the drug in mice whenTable 1: LD50 value estimation for Hepacare
 herbal formu-
lation in mice.
Hepacare Intragastric dose (mg/kg)
Phase I 10 100 1000
Mortality 0/3 0/3 0/3
Phase II 1600 2900 5000
Mortality 0/3 0/3 2/3
LD50 3807.89compared with the group that received no treatment after
24 h of oral administration of the drug. We also noted a
significant (p < 0.05) increase in the mRNA expression level
in mouse liver homogenates of both IL-6 and TNF-a in the
group treated with 2500 mg/kg b.w. compared with the
negative control group. After normalization with a house-
keeping gene (GADPH), which was used as a positive
expression control, increased values were noted for both IL-6
and TNF-a mRNA expression in the 2500 mg/kg b.w.
treated group; however, these increased levels were not sta-
tistically significant (p > 0.05) (Figure 2).
Sub-chronic toxicity studies
Physical and weight examination of organs
Our findings showed that Hepacare did not significantly
increase or decrease the relative heart, liver, kidney, spleen or
lung weights (p> 0.05) after 28 days of administration in any
of the tested doses when compared with the negative control
group. There were also no noticeable visible pathological
changes in the organs (Table 2).
Biochemical parameters
Our results, after 28 days of oral treatment of the herbal
formulation in mice, are shown in Figure 3. We observed a
significant increase (p < 0.05) in ALP activity in the
750 mg/kg bw treated group compared with the control
group. There was also a significant increase in the ALT,
AST, and ALP activity in the 2500 mg/kg treated group
compared with the control group. However, there was no
significant difference (p > 0.05) observed for ALT, AST
and ALP in the 250 and 500 mg/kg treatment groups. For
the non-enzymatic specific markers, there was a significant
(p < 0.05) elevation of bilirubin and total proteins in the
2500 mg/kg b.w. treated group. There was no significant
(p > 0.05) elevation in either of these parameters in the
groups treated with doses lower than 2500 mg/kg b.w.
Haematological parameters
Findings from our haematological analysis of blood
sampled from mice after the 28-day sub-chronic oral treat-
ment with the herbal drug are presented in Figure 4. There
was a significant increase (p < 0.05) in monocyte counts in
the 750 and 2500 mg/kg treatment groups when compared
with the control group. However, there was no significant
difference (p > 0.05) observed between the treatment and
control groups regarding the PCV, WBC, neutrophil and
lymphocyte levels.
Histological liver and kidney tissue examinations
Photomicrographs of hepatic and renal tissues of mice
after the 28-day treatment with 250, 500, 750 and 2500 mg/kg
b.w. of the herbal formulation are shown in Figures 5 and 6.
The observed effects of the formulation after this period
included macrovesicular steatosis, which progressed from
moderate (in the 250 and 500 mg/kg b.w. treated groups)
to severe (in the 750 and 2500 mg/kg treated groups);
congestion of blood vessels, which progressed from mild
(in the 250 mg/kg b.w. treated group), marked (in the
500 mg/kg b.w. treated group), to severe (in the 750 and
2500 mg/kg b.w. treated groups); and periportal
inflammation, which ranged from mild (in the 250 mg/kg
Figure 1: Effects of Hepacare on IL-6 and TNF-a gene expression against a DNA/HaeIII marker (72 bpe1353 bp) in bone marrow cells
of mice following 24 h of treatment. Lanes A ¼ control; B ¼ 250 mg/kg; C ¼ 500 mg/kg treatment; D ¼ 2500 mg/kg treatment group.
Pro-inflammatory and toxicological evaluation of Hepacare 317b.w. treated group), moderate (in the 500 and 750 mg/kg b.w.
treated groups) to severe (in the 2500 mg/kg b.w. treated
group) (Figure 5). Renal histological examination in this
study also showed similar patterns of progressive damage
(Figure 6) with increasing concentrations of the herbal
formulation in mice. This included mild (in the 250 and
500 mg/kg b.w. treated groups) to moderate (in the 750
and 2500 mg/kg b.w. treated groups) congestion, as well as
mild (in the 250 and 500 mg/kg treated groups) to
moderate (in the 750 mg/kg b.w. treated group) interstitial
inflammation. Multiple zones of severe inflammation,
granular tissue formation and mild blood congestion were
seen in the renal tissue of the 2500 mg/kg treated group.Genotoxicity studies
The results of our comet assay are shown in Figures 7 and
8. The lengths of the comet tails were quantified by pixel
intensity measurements of photomicrographs of stained
DNA after electrophoresis (Figure 7). Our results showed a
significant difference (p < 0.05) in tail lengths between the
positive control-group treated with cyclophosphamide (a
known genotoxic agent) and all other treatment groups
(Figure 8).Figure 2: Band pixel density (%) after normalization with a
housekeeping gene (GADPH) expressed as the mean  SEM of 3
replicate measurements.Discussion
Acute toxicity of Hepacare
Toxicological assessments are necessary tools used to
evaluate the possible health risks in humans that may be
caused by drug compounds or herbs.3,15 Herbal medicines,
which are often used without formal professional
prescription, may occasionally result in abuse and
overdose.3 The median lethal dose is an appropriate
estimation of the safety of a chemical or drug that has been
useful in providing information for consumer safety.16
From our results (Table 1), the LD50 of the herbal
formulation places it within the category of substances
with “low” oral toxicity in the OECD globally harmonized
classification system.15 It is very unlikely that the herbal
formulation would be harmful when taken at the regimen
indicated on the packaging of the herbal formulation in
which 1 capsule (250 mg) is expected to be taken in three
separate doses daily.Effect of Hepacare on pro-inflammatory markers for
toxicity
Inflammation is a tightly regulated biological response to
adverse stimuli. Acute exposure to chemical substances
originating from plants can lead to acute cytokine-mediated
inflammatory responses.17 TNF-a and IL-6 are two pro-
inflammatory cytokines that are implicated in acute inflam-
mation events that lead to tissue damage and organ failure, a
direct response of the increase in mRNA expression of these
cytokines during the onset of inflammation.18,19 In our study,
RT-PCR was used to assess the effects of the herbal
formulation on the TNF-a and IL-6 mRNA expression
levels in mouse liver tissue. Our results showed no significant
(p > 0.05) increase in the mRNA expression of either TNF-a
and IL-6 dosed with 250, 500 or 750 mg/kg b.w. after a 24 h
period. However, there were some pro-inflammatory mod-
ulation activity changes in mice given the 2500 mg/kg treat-
ment, but this increase was not significant (p > 0.05) when
normalized with GADPH (Figure 2). In a similar study, C.
frutescens was demonstrated to increase the IL-6 and TNF-
Table 2: Effects of Hepacare on the relative organ weights of mice after 28-day sub-chronic treatment.
Sample Control 250 mg/kg 500 mg/kg 750 mg/kg 2500 mg/kg
Mean group weight 22.45  1.54 23.26  2.87 21.34  0.55 22.43  2.87 21.26  3.34
Liver body/organ weight 65.45  1.87 63.04  2.92 66.84  3.87 65.48  2.41 68.80  2.50
Kidney body/organ weight 10.27  0.32 9.65  0.32 9.52  0.45 9.78  0.51 9.65  0.14
Spleen body/organ weight 2.53  0.10 2.45  0.13 2.52  0.12 2.54  0.07 2.31  0.20
Heart body/organ weight 5.53  0.63 6.64  0.65 6.52  0.74 5.65  0.54 6.43  2.64
Values represent mean  SEM of 5 replicates. p > 0.05.
A.H. Adebayo et al.318a levels significantly.20,21,17 However, it was also shown in
other investigations that capsaicin, which was isolated from
C. frutescens, is a potent anti-inflammatory substance.22
This suggests that capsaicin may not be activated unless it
is in a pure state. It is therefore possible that herbeherb
interactions that have been described in previous
investigations of other polyphenols present in the herbal
mixture may activate capsaicin’s anti-inflammatory proper-
ties, or other polyphenols and flavonoids with anti-
inflammatory activities are present that mitigate the active
principles that induce acute inflammation in the C. frutescens
component of the herbal mixture.23
Sub-chronic toxicity of Hepacare in mice
This herbal formulation is currently sold and employed
for the treatment of chronic liver diseases among others
ailments, as discussed in Ishola et al.9 However, it has been
suggested that long-term exposure of the herbal formula-
tion can lead to chronic ailments in users.24 Therefore, a
chronic toxicity study of the herbal formulation is also of
necessary importance for the assessment of the drug’s
safety. Changes in the relative organ weights form one such
assessment of organ weights affected by alterations inFigure 3: Effect of Hepacare on biochemical parameters in mice, inc
transferases (AST), (c) alkaline phosphatase (ALP), (d) total bilirubin (
replicates; *p < 0.05.physiology that is caused by toxic chronic events.25 There
were no significant (p > 0.05) changes in the relative heart,
liver, kidney, spleen and lung tissue weights following
macroscopic examination post mortem of the mice after
the 28 day treatments (Table 2). However, organ injuries,
including the liver and kidney, may be microscopic in
nature and can also be observed for disease manifestation
in sub chronic events.25 In the liver, hepatocyte injury by
herbal formulation may impair normal processes of
synthesis and/or elimination of triglycerides, which
constitute other important liver functions. These lead to
increased accumulation of lipids in the macrovesicles
(macrovesicular steatosis), which give rise to inflammation
and associated physiological responses.26 Kidneys are also
involved in xenobiotic processing and are also susceptible
to damage by medicinal herbs. Haemorrhage has been
linked to high concentrations of the herbal medicine’s
secondary metabolites.3 In our study, we found evidence of
progressive damage in the liver and the kidney with
increasing concentrations of the herbal formulation given
to mice over a 28-day period, and they were statistically
significant at higher doses (Figures 5 and 6). However,
contrary observations were made in a previous study
conducted by Adebayo et al.13 where Olax subsorpioidealuding (a) alanine aminotransferases (ALT), (b) aspartate amino-
Bilirubin) and (e) total protein. Values represent mean  SEM of 5
Figure 4: Effect of Hepacare on haematological parameters in mice, including (a) pack cell volume (PCV), (b) monocytes, (c) lym-
phocytes, (d) neutrophils and total white blood cells (WBC). Values represent the mean  standard error of mean (SEM) of 5 replicates;
*p < 0.05.
Pro-inflammatory and toxicological evaluation of Hepacare 319extracts dosed in albino Wistar rats at 250, 500 and 750 mg/
kg per body weight revealed no hepatic or renal damage after
treatment after the same duration. Some studies have
described herbeherb interactions that lead to the
potentiation of harmful phytochemicals within
formulations that can counteract beneficial (or harmful)
effects in co-administration, which may be a reason for this
discrepancy.3 As common mechanisms for damage are as a
result of high concentrations of phytochemicals in tissueFigure 5: Hepatic tissue photomicrographs (H&E 400) of mice oralcells, it is unlikely that polyphenols and flavonoids would
elicit significant damage to either liver or renal tissue at
lower concentrations in mice.
Effects of Hepacare on biochemical serum markers of
toxicity
The liver is susceptible to injury following chronic expo-
sure to drugs and xenobiotics. Aspartate aminotransferasely treated with Hepacare at 250, 500, 750 and 2500 mg/kg b.w.
Figure 6: Renal tissue photomicrographs (H&E 400) of mice orally treated with Hepacare at 250, 500, 750 and 2500 mg/kg body
weight.
A.H. Adebayo et al.320(AST or serum glutamic oxaloacetic transaminase, SGOT),
alanine aminotransferase (ALT or serum glutamic pyruvic
transaminase, SGPT) and alkaline phosphatase (ALP) are
serum markers of hepatic injury and hepatocellular necrosisFigure 7: Pictographs of stained DNA in bone marrow cells after sing
in mice dosed with 100 or 1000 mg/kg compared with cyclophospham
treatment experiment. Red markings show software capture of cells bthat have been used to assess the extent of liver damage
following chronic exposure to harmful xenobiotics.27,28 It
may be important to note that AST and ALP are also
found in cells other than the liver and may indicate injuryle-cell gel electrophoresis analysed after treatment with Hepacare
ide and a group receiving no treatment after 24 h in a single dose
y OpenComet in ImageJ (NIH, USA).
Figure 8: Comet tail lengths from a comets assay analysed with
OpenComet in ImageJ (NIH, USA) showing the effect of Hep-
acare in mice compared with cyclophosphamide and a group
receiving no treatment after 24 h at single dose treatments. Values
represent mean  standard error of mean (SEM) of 5 replicates;
ap < 0.05.
Pro-inflammatory and toxicological evaluation of Hepacare 321to other tissues.27e29 Results from the 28 day sub-chronic
experiment in this study showed a significant (p < 0.05)
elevation of serum AST and ALT levels in the 2500 mg/kg
dose group and significant (p < 0.05) elevations of serum
ALP in the 750 and 2500 mg/kg dose groups in mice
compared with the control. No significant (p > 0.05) eleva-
tions in serum AST, ALT or ALP levels were observed at
lower doses (Figure 3aec). A similar study conducted on
O. subsorpioidea in Wistar rats also showed a significant
(p < 0.05) increase in serum AST, ALT and ALP levels
when dosed at 1000 mg/kg b.w. Large amounts of bilirubin
may be found in the blood when it accumulates and re-
enters circulation due to intrahepatic obstruction and this
can lead to severe liver or kidney injury.30 High total protein
levels in the blood may also indicate liver or kidney injury
due to chronic inflammation.31 Our results also showed a
significant (p < 0.05) elevation of bilirubin and total
protein in the serum of the 2500 mg/kg b.w. treated group.
There was no significant (p > 0.05) increase in bilirubin
and total protein in the lower treatment groups
(Figure 3dee). Adebayo et al.13 also demonstrated that a
lower dose (500 mg/kg) significantly (p < 0.05) increased
the total bilirubin levels. It is unlikely that liver damage
would occur at moderate doses of the herbal drug at even
moderately high doses over extended treatment periods in
murine subjects (i.e., <500 mg/kg).
Effects of Hepacare on haematological serum markers for
toxicity
Packed cell volume (PCV) is relevant in diagnosing
anaemia and polycythaemia that are linked to the presence of
heavy metals (e.g., lead and cadmium) and other chemical
impurities (e.g., from insecticides and herbicides) in herbs
and herbal medicines.32,3 In our study, there was no
significant difference (p > 0.05) observed in the PCV values
when all of the treatment groups were compared with the
control; therefore, it is unlikely that the herbal formulation
drug possess toxic blood impurities (Figure 4a). Other
blood cellular elements (i.e., WBCs, which include
neutrophils, eosinophils, basophils, lymphocytes andmonocytes) protect the body against infection and foreign
bodies and may be elevated in the serum in these events.
Elevated serum monocytes may be linked to chronic
inflammation and stress amongst other diseases.33,34 Our
results (Figure 4b) showed significantly (p < 0.05) elevated
monocyte levels in the 750 and 2500 mg/kg treatment
groups. Our histopathological observation in this study,
which showed marked inflammation in hepatic tissues of
these two treatment groups, is consistent with this finding.
Lymphocytes (B cells, T cells and natural killer cells)
constitute the adaptive immune system and are usually
elevated in recognition to infection by pathogens.
Neutrophils are the most abundant leucocyte and are
usually the first responders to inflammation and are usually
elevated in acute inflammation.33,34 There was no
significant increase (p > 0.05) in the lymphocyte or
neutrophil percentages or the white blood cell counts in the
serum levels of any treatment group compared with the
controls (Figure 4cee). In a study conducted by Adebayo
et al.13 lymphocyte and neutrophil percentages also showed
no significant changes when one of the ingredients of the
herbal formulation was tested in Wistar albino rats. It is
thus improbable that the use of the herbal drug would
cause or support infection.
Genotoxicity assessment by single-cell gel electrophoresis
The comet single cell gel assay is a sensitive method for
quantifying DNA damage in low amounts in almost all
mammalian cells.35,36 In this study, the comet single cell gel
assay demonstrated no evidence that the herbal formulated
drug was potentially genotoxic (Figures 7 and 8). Certain
plants have been demonstrated to be genotoxic due to the
content of certain phytochemicals present in them that
form adducts with DNA that interfere with normal DNA
repair mechanism in various cells.37e41 In previous studies,
capsaicin, which is linked to C. frutescens, has been
demonstrated to be carcinogenic in humans.42 In other
reports, however, C. frutescens was used as an effective
treatment for cancers and this was largely attributed to the
antioxidant properties of the plant.20 Herbeherb
interactions were described by Brantley et al.23 wherein
may lie the reason for this paradox. The presence of other
herb components in the herbal formulated drug that
protect DNA and stimulate repair may act in mitigating
capsaicin’s DNA damaging effect, if any, or be involved in
keeping capsaicin in its inactive state.
Conclusions
Owing to the lack of experimental data on Hepacare’s
safety profile, a toxicological evaluation was performed us-
ing mice as an experimental model. For the first time, this
study provides relevant data and additional evidence to
support the herbal formulation usage as a therapeutic rem-
edy on a broader scale. Additionally, this study reveals that
although the herbal formulation at high doses may cause a
significant increase in serum levels of certain biochemical
parameters, namely, AST, ALT, ALP, total bilirubin and
total protein, and significant histological changes in both
hepatic and renal tissue, it is unlikely to do so at doses below
A.H. Adebayo et al.322500 mg/kg b.w. in mice. Furthermore, from our pro-
inflammatory cytokine mRNA expression data, namely,
IL-6 and TNF-a, this study shows that acute inflammation is
an unlikely mechanism for tissue injury in the liver at high
dose treatments of the drug. However, the haematology re-
sults showed that inflammation may be important in chronic
conditions. The results in this study also show that the drug
may not be genotoxic. This study also suggests the interplay
of possible polyphenol active principles in herbeherb in-
teractions that seem to control the general properties of the
drug blend as a whole, which sometimes is contrasting to the
properties exhibited for each individual ingredient studied in
isolation. It is recommended that further studies be carried
out to isolate and identify the active components and
determine their individual activities as well as molecular
modes of action and explain the possible harmful (or bene-
ficial) interactions between them. In conclusion, Hepacare
may not induce significant toxic effects when administered in
mice below 500 mg/kg b.w. in both acute and sub-chronic
conditions and thus may be safe for use at the recom-
mended therapeutic dose; however, patients who have pro-
longed liver diseases should exercise caution to avoid further
complications.
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